A股異動 | 海利爾(603639.SH)漲近6% 山東海利爾2000噸/年丙硫菌唑原藥項目、研發中心擴建項目結項
格隆匯3月8日丨海利爾(603639.SH)漲近6%,報26.38元,股價創近2年來新高,總市值63億元。海利爾公佈,2021年3月5日,公司召開第四屆董事會第三次會議和第四屆監事會第三次會議,審議通過了《關於公司首次公開發行股票募投項目結項並將節餘募集資金永久性補充流動資金的議案》,同意公司將首次公開發行股票募投項目(山東海利爾2000噸/年丙硫菌唑原藥項目、研發中心擴建項目)進行結項,並將節餘募集資金永久性補充流動資金。上述事項尚需提交公司股東大會批准。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.